These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 8120558)

  • 1. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose mercaptopurine and intermediate-dose cytarabine during first remission of acute myeloid leukemia.
    Canpolat C; Jeha S; Lockhart S; Ramirez I; Zipf T; Pinkel D
    Cancer Invest; 1997; 15(2):121-6. PubMed ID: 9095207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
    Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
    Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of continuous infusion Ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia.
    Laver J; Shearer P; Krance R; Hurwitz CA; Srivastava DK; Weinstein HJ; Mirro J
    Leuk Lymphoma; 1997 Aug; 26(5-6):589-93. PubMed ID: 9389365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML).
    Leahey A; Kelly K; Rorke LB; Lange B
    J Pediatr Hematol Oncol; 1997; 19(4):304-8. PubMed ID: 9256828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
    Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
    J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.